Showing 2251-2260 of 4944 results for "".
- Biofrontera Acquires Cutanea Life Scienceshttps://practicaldermatology.com/news/biofrontera-acquires-cutanea-life-sciences/2459959/Biofrontera Inc., USA entered into an agreement to acquire all shares in Cutanea Life Sciences, Inc., USA through its subsidiary Biofrontera Newderm LLC as the acquirer, with Maruho Co., Ltd., Japan as the seller. Maruho holds approximately 20 percent of Biofrontera AG. Cutanea is a US-based phar
- Lead Pharma Begins Phase I Trials with SAR441169 Candidate Treatment for Psoriasishttps://practicaldermatology.com/news/lead-pharma-to-begin-phase-i-trials-with-sar441169-candidate-treatment-for-psoriasis/2459962/Lead Pharma, a pharmaceutical company developing innovative medicines for the treatment of immunological and oncological indications, achieved a fourth milestone under its license & collaboration agreement with Sanofi, triggering an undisclosed milestone payment. The milestone payment is link
- Galderma Collaborates with Nespresso to Offer Patient Loyalty Incentive Programhttps://practicaldermatology.com/news/galderma-collaborates-with-nespresso-to-offer-patient-loyalty-incentive-program/2459968/Galderma Laboratories, L.P., recently teamed up with Nespresso to offer a new rewards program for patients who seek Restylane treatments from aesthetic professionals. With a qualifying purchase of Restylane dermal fillers, aesthetic professionals will receive a set of vouchers for complimentary N
- Constellation Alpha Capital Corp. Signs Letter of Intent to Acquire DermTech, Inc.https://practicaldermatology.com/news/constellation-alpha-capital-corp-signs-letter-of-intent-to-acquire-dermtech-inc/2459970/Constellation Alpha Capital Corp., a special purpose acquisition company, has executed a non-binding Letter of Intent to merge with DermTech, Inc., a molecular genomics company with an initial focus on skin cancer. DermTech markets and develops products that facilitate the early detection of skin
- Study: Port Wine Stain Laser Treatment Is Safe and Effective in Infants Without Anesthesiahttps://practicaldermatology.com/news/study-port-wine-stain-laser-treatment-is-safe-and-effective-in-infants-without-anesthesia/2459974/Recent concerns about the repetitive use of general anesthesia in children younger than 3 have placed greater importance on the controversy surrounding the timing of port-wine stain laser treatment, but a new
- Biopelle Launches Emepelle to Address Estrogen Deficient Skinhttps://practicaldermatology.com/news/biopelle-launches-emepelle-to-address-estrogen-deficient-skin/2459979/Biopelle, Inc. has launched Emepelle, the first and only clinically proven skincare line that safely and effectively helps address Estrogen Deficient Skin (EDS). Emepelle features MEP Technology, a patented, specifically designed ingredient that helps
- Bimekizumab Provides Long-Term Skin Clearance for Psoriasis Patients in Phase 2b Studyhttps://practicaldermatology.com/news/ucbs-bimekizumab-performs-well-in-extension-study/2459873/UCB’s bimekizumab demonstrated long-term maintenance of complete or almost complete skin disease resolution for psoriasis patients, according to results from the Phase 2b BE ABLE 2 Extension Study presented at the 2019 American Academy of Dermatology Annual Meeting (AAD) in Washington,
- Sentient Lasers Unveils Dot Demo Servicehttps://practicaldermatology.com/news/sentient-lasers-unveils-dot-demo-service/2459886/Sentient Lasers has launched its new,
- Cutera to Unveil excel V+ Next Generation Laser Platform at AAD Annual Meetinghttps://practicaldermatology.com/news/cutera-to-unveil-excel-v-next-generation-laser-platform-at-aad-annual-meeting/2459888/Cutera, Inc. has launched its excel V+ laser platform, which the company describes as a technological advancement that includes 50 percent more power and treatment speed, optimized delivery systems and parameters for treating vascular lesions and pigmentation concerns. Cutera will unveil the exce
- TARGET PharmaSolutions Launches Real-World Study to Advance the Understanding of AD and Other IMISCshttps://practicaldermatology.com/news/target-pharmasolutions-launches-target-derm-real-world-study-to-advance-the-understanding-of-atopic-dermatitis-and-other-immune-mediated-inflammatory/2459890/TARGET PharmaSolutions, Inc., has launched its latest large-scale observational study, TARGET-DERM (NCT03661866). The study will deliver real-world evidence for several immune-mediated inflammatory skin conditions (IMISCs), initially focusing on patients with atopic dermatitis. TARGET-DERM&